Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Marriott International Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Marriott International Inc trades at $375.18 (market cap $96.87B). The key difference: Marriott International Inc is far larger — about 10.9× Kymera Therapeutics Inc. Common Stock's market cap, and Marriott International Inc pays a 0.79% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Marriott International Inc for 164 Days on average.
| KYMR | MAR | |
|---|---|---|
Market Cap | $8.87B | $96.87B |
Volume | 779,107 | 755,878 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $402.54 |
52-Week Low | $55.80 | $259.04 |
Typical Hold Time | 0 Days | 164 Days |
Enterprise Value | $8.26B | $114.19B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marriott International (MAR) trades at $371.82, up 0.68% today, near its resistance at $372. The stock shows bullish technical signals with strong moving averages, though the RSI indicates mild overbought conditions. Fundamentally, revenue grew to $26.19B in 2025 with a net income margin of 9.62%, but the P/E of 38.46 and P/B of 443.63 reflect premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share.
The outlook for MAR is positive, supported by robust travel demand and strategic initiatives like new technology partnerships. However, risks include high debt levels, with debt-to-asset ratio rising to 55.17% in 2024, and sensitivity to economic cycles. Analysts maintain a consensus price target of $388.93, suggesting moderate upside, but investors should weigh valuation concerns against growth prospects in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
